ESSENTIAL PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of ESSENTIAL PHARMA is 1.5% (moderate). The 2025 annual accounts show equity of €102,710 and a net result of -€26,834. Equity is growing by about 21% per year across the filed financial years. Its solvency ranks better than 35% of 12,578 sector peers (NACE 47, financial year 2025). The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
09-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Weakest financial yearnet -€26,834
Net result drops to -€26,834, the lowest in the series.
03-07
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
26-09
Gazette deed
Resignation: Essential Management (director)Appointment: Essential Management (director) · Permanent representative: Erwin Gillissen4 facts ▸
Gazette deed
Resignation: Essential Management (director)
Appointment: Essential Management (director) · Permanent representative: Erwin Gillissen4 facts ▸
- General meeting, 01-07-2024
- Director resignation, Essential Management
- Director appointment, Essential Management (director)
- Permanent representative, Erwin Gillissen
01-07
NBB filing
Annual accounts filed
financial year 2023 · full format
2023
31-12
Financial
Equity above €100,000equity €102,808 ▲81.9%
A profit in every financial year since 2022 builds equity to €102,808.
30-06
NBB filing
Annual accounts filed
financial year 2022 · micro format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 2 deeds read
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.